Western University
London, ON, Canada
Dr. Lillian Barra is an Associate Professor in the Department of Medicine, Division of Rheumatology at Western University, cross-appointed to the Departments of Microbiology and Immunology, Epidemiology and Biostatistics. She completed her M.D. and Postgraduate training in Internal Medicine and Rheumatology at Western University and her Master of Public Health at Harvard University. She established the first interdisciplinary vasculitis clinic (IVASC) in Southwestern Ontario and is President of the Canadian Vasculitis Network (CanVasc). Her research focuses on understanding the pathogenesis and impact of chronic autoimmune vascular diseases. The research is translational involving humanized mouse models, biomarker studies, evidence synthesis, and observational epidemiologic studies.
Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Otsuka: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
12S136: CARE: Central Nervous System Vasculitis
Sunday, November 12, 2023
2:00 PM – 3:00 PM PT
Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Otsuka: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
1727: Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Otsuka: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
1728: A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Tuesday, November 14, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Otsuka: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
